What are the best digital therapeutics companies?

This blog post has been written by the person who has mapped the digital therapeutics market in a clean and beautiful presentation

Digital therapeutics companies are transforming healthcare by delivering evidence-based interventions directly through software.

The market leaders combine strong revenue streams, clinical validation, and strategic partnerships with major healthcare players. Companies like Omada Health and Medtronic dominate with hundreds of millions in annual revenue, while emerging players secure significant funding rounds exceeding $50 million.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Who are the top digital therapeutics companies by revenue, effectiveness, and market presence?

Omada Health leads the revenue race with $357 million in 2024, followed by Canary Health at $100 million and CureApp at $90.6 million.

Medtronic dominates with $31.2 billion total revenue, though their DTx division represents a smaller portion of overall business. GAIA AG generated $82 million specifically from therapeutic apps and clinical decision tools across European markets. Voluntis reached $22.6 billion in partnerships through their FDA-cleared Insulia diabetes platform.

Product effectiveness separates leaders from followers through published peer-reviewed studies. Omada Health demonstrates weight loss and glycemic control improvements across multiple randomized controlled trials. CureApp achieved Japan's first regulatory approval for smoking cessation in 2019, with clinical trials showing significantly higher quit rates compared to standard care.

Market presence requires both geographic reach and payer adoption. UnitedHealth Group now covers 43% of members with DTx solutions as of 2024. Germany's DiGA program processed over 9 million reimbursable prescriptions by December 2023, creating sustainable revenue streams for European players.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

Which companies raised the most funding in 2024-2025, and from which investors?

Pear Therapeutics secured the largest single round with $64 million in Series C funding led by Temasek and 5AM Ventures.

Click Therapeutics followed with $48.5 million from Dassault Systèmes, Otsuka, and Boehringer Ingelheim specifically for their CT-132 migraine prevention platform. Sidekick Health obtained €42 million in venture debt from the European Investment Bank, demonstrating institutional confidence in European DTx companies.

Biofourmis raised $59.2 million across multiple rounds from healthcare-focused funds including GV and NEA. Buoy Health achieved $400.5 million in total funding from strategic and VC firms, though this spans AI triage beyond pure DTx applications.

Strategic investor involvement signals industry maturation. Pharmaceutical giants like Otsuka and Boehringer Ingelberg now directly fund DTx development rather than waiting for acquisition opportunities. European government backing through institutions like EIB provides alternative funding sources for companies targeting regulated healthcare markets.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

How much total investment flowed into digital therapeutics in 2024-2025 compared to previous years?

Digital therapeutics attracted $19.72 billion combined across 2024-2025, representing a 26% compound annual growth rate since 2021.

The 2024 funding totaled $8.73 billion, while 2025 reached $10.99 billion to date, suggesting an accelerating investment pace. This contrasts sharply with broader digital health funding, which declined from a $29.2 billion peak in 2021 to $10.1 billion in 2024.

DTx-specific investment bucked the broader trend with growth from approximately $7 billion in 2023 to $8.73 billion in 2024. The 2025 pace suggests total annual funding could reach $11 billion by year-end, representing the strongest funding environment in DTx history.

Geographic distribution shows North America capturing roughly 60% of funding, Europe 25%, and Asia-Pacific 15%. However, Asia-Pacific funding declined 19% year-over-year to approximately $2 billion across 244 deals in 2024, primarily due to reduced Chinese venture activity.

Which companies secured backing from pharmaceutical, insurance, or tech giants under what strategic conditions?

Strategic partnerships increasingly involve co-development agreements rather than simple licensing deals.

Which geographies show the most growth in digital therapeutics funding and what new hubs are emerging?

North America maintains dominance with $4.50 billion in DTx revenue representing 66% global share, but Europe shows the fastest funding growth at 27% year-over-year.

Germany leads European development through its DiGA reimbursement program, processing over 9 million prescriptions and creating sustainable revenue models. The European Investment Bank's €35 million debt facility to Sidekick Health signals institutional support for European DTx scaling across multiple countries.

Asia-Pacific presents mixed signals with Japan and China emerging as regulatory leaders while overall regional funding declined. Japan approved 14 Software as Medical Device (SaMD) applications under MHLW pathways, creating clear commercialization routes. China approved 235 DTx applications focusing on neurological and ophthalmic diseases, though venture funding contracted.

Emerging hubs include India and Latin America, driven by large chronic disease populations and increasing smartphone penetration. These regions attract early-stage funding for localized solutions addressing diabetes, hypertension, and mental health at scale.

What notable awards, grants, and recognition have digital therapeutics startups received recently?

FDA breakthrough device designations represent the most valuable recognition, with Click Therapeutics receiving breakthrough status for their schizophrenia DTx developed with Boehringer Ingelheim.

Multiple NIH SBIR and STTR grants supported mental health and chronic disease DTx platforms, providing non-dilutive funding for clinical development. These federal grants typically range from $250,000 to $2 million and include commercialization pathways.

Industry awards highlighted technical innovation leaders. MedTech Breakthrough recognized Kaia Health and Atomwise for pain management and AI therapeutics respectively. Tenovi received Silver at Digital Health Awards Spring 2025 for medication adherence solutions.

Digital Health Summer Schools Awards spotlighted NHS DTx implementation leaders, demonstrating successful integration within public healthcare systems. These recognitions increasingly focus on real-world evidence generation rather than purely technical capabilities.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

If you need to-the-point data on this market, you can download our latest market pitch deck here

Which companies made significant R&D breakthroughs in 2025, particularly in mental health, diabetes, and oncology?

Mental health DTx achieved major advances through AI-driven cognitive behavioral therapy delivered via mobile VR platforms.

Akili's EndeavorRx expanded beyond pediatric ADHD into adult attention disorders using gamified neurocognitive training. Happify demonstrated 30% reductions in PHQ-9 depression scores through high-engagement apps combining CBT with personalized content algorithms.

Diabetes management breakthroughs focused on real-time insulin titration algorithms. Voluntis integrated advanced dosing recommendations within their Insulia platform, achieving more precise glycemic control through continuous glucose monitor data integration. CureApp expanded beyond smoking cessation with their hypertension DTx reducing systolic blood pressure by 6 mmHg at 24 weeks in Japanese clinical trials.

Oncology innovations centered on immunotherapy symptom management. Kaiku Health developed specialized modules for Roche's immunotherapy protocols, enabling real-time side effect tracking and intervention recommendations. These platforms reduce emergency department visits while improving treatment adherence.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

What are the most anticipated product launches expected in 2026 and which companies are developing them?

Biofourmis plans Q2 2026 launch of their AI nitrogen balance platform for heart failure management, representing the first DTx addressing this specific cardiac complication.

Which companies achieved regulatory approvals recently and for what specific treatments?

Click Therapeutics achieved the most significant recent approval with CT-132 becoming the first FDA-cleared digital therapeutic for episodic migraine prevention in 2025.

The FDA's De novo pathway provided routes for novel DTx applications. NightWare received approval for PTSD sleep disturbance management through smartwatch-based intervention. RelieVRx gained both FDA and CE clearance for pain relief using virtual reality exposure therapy.

European approvals focused on CE MDR compliance for broader market access. Sleep Thera from Bell Therapeutics achieved CE MDR marking for insomnia treatment, enabling prescription across EU markets. Multiple German DTx companies gained DiGA eligibility, allowing direct reimbursement through statutory health insurance.

Japan maintained its leadership in Asian DTx approvals through the MHLW Software as Medical Device pathway. Fourteen applications received approval, primarily targeting neurological and metabolic conditions with strong clinical evidence requirements.

If you want actionable data about this market, you can download our latest market pitch deck here

What technologies drive competitive advantage for the top digital therapeutics players?

Artificial intelligence and machine learning enable personalized dosing and predictive analytics that separate leaders from basic app developers.

Voluntis leverages AI algorithms for insulin titration recommendations within their Insulia platform, adjusting dosages based on continuous glucose monitoring data and patient behavior patterns. Biofourmis applies machine learning to cardiac monitoring, predicting heart failure exacerbations days before clinical symptoms appear.

Virtual reality and gamification create engagement levels impossible through traditional interfaces. Akili's EndeavorRx uses neurocognitive gaming to treat pediatric ADHD, while AppliedVR delivers exposure therapy for pain management through immersive environments.

Wearables integration enables passive monitoring that reduces patient burden while increasing data quality. Propeller Health embeds sensors in COPD inhalers to track medication adherence and environmental triggers automatically.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

What acquisitions, mergers, and strategic exits occurred since 2024?

Teladoc Health's $18.5 billion acquisition of Livongo represents the largest DTx-related transaction, though it encompasses broader virtual care consolidation.

Novartis acquired DTx Pharma's FALCON RNA platform for up to $1 billion, targeting neuroscience pipeline expansion through digital biomarker integration. This acquisition demonstrates pharmaceutical companies' shift toward internal DTx development rather than partnership models.

Click Therapeutics acquired Better Therapeutics in an undisclosed transaction to strengthen their obesity and cardiometabolic portfolio. Sidekick Health acquired German company aidhere, including their zanadio obesity management platform, for European market expansion.

Strategic exits remain limited compared to traditional health tech, indicating most DTx companies pursue partnerships or continued independent growth rather than acquisition exits. This pattern suggests the market remains in expansion rather than consolidation phase.

Which early-stage companies show the most promise and are being tracked by top VCs?

Biofourmis leads early-stage promise with $59.2 million from GV and NEA for personalized cardiology platforms combining AI with remote monitoring.

Buoy Health attracted $400.5 million from Lux Capital and F-Prime for AI-powered triage and navigation systems. Limbix secured $217.5 million from Y Combinator and Andreessen Horowitz for VR exposure therapy targeting anxiety and PTSD.

Mindset Health raised $195.1 million from White Fund and Capricorn for hypnotherapy applications delivered through mobile platforms. Meru Health obtained $126 million from Y Combinator and Maveron for digital burnout prevention programs targeting workplace mental health.

VC tracking focuses on companies addressing large patient populations with measurable clinical outcomes. Early-stage DTx companies demonstrating user engagement above 60% and clinical efficacy through pilot studies receive priority attention from healthcare-focused funds.

Curious about how money is made in this sector? Explore the most profitable business models in our sleek decks.

Conclusion

Sources

1. EmergenResearch Top 10 DTx Companies, 2024
2. QuickMarketPitch Funding Summary, 2025
3. Seedtable Best Digital Therapeutics Startups
4. Fierce Healthcare Digital Health Funding, 2024
5. DTx Alliance Pharma Partnerships Blueprint
6. Elekta Kaiku Strategic Partnership
7. BH Business CT-132 Funding & Collaborations, 2025
8. GlobeNewswire DTx Market & Payer Coverage, 2025
9. Statista Market Forecast 2025
10. GalenGrowth Q1 2025 Digital Health Funding
11. GalenGrowth Asia-Pacific Digital Health Funding 2024
12. Nature Digital Health China DTx Approvals
13. MedTech Breakthrough 2025 Winners
14. Tenovi Digital Health Awards Spring 2025
15. Digital Health Summer Schools Awards 2025
16. LinkedIn 20 Innovative DTx Companies 2025
17. medRxiv CureApp HT Real-World Study
18. NeurologyLive FDA Approves CT-132 for Migraine, 2025
19. Binariks Top 16 DTx Companies 2025 Forecast
20. Connect.org DTx Journey
21. GalenGrowth Q1 2025 Digital Health Funding Trends